Graves’ Disease Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration by DelveInsight

Graves’ Disease Clinical Trials

DelveInsight’s “Graves’ Disease Pipeline Insight, 2025”, report delivers a comprehensive analysis of the evolving therapeutic landscape for Graves’ Disease (GD). With more than 10+ emerging treatment candidates in clinical and preclinical development, and 8+ leading pharmaceutical and biotech companies working on innovative therapies, the Graves’ Disease market is witnessing significant transformation.

The report provides in-depth insights into clinical trials, drug mechanisms of action, routes of administration, product types, and ongoing research collaborations, making it an essential resource for stakeholders, investors, and healthcare professionals.

Unlock detailed insights into the Graves’ Disease therapeutics by downloading the comprehensive report from DelveInsight @ Graves’ Disease Pipeline Outlook

Key Takeaways from the Graves’ Disease Market Report

• As per DelveInsight’s estimates, Graves’ disease is the primary cause of hyperthyroidism, responsible for 60–80% of cases. Despite this prevalence, it is relatively uncommon, impacting roughly 1.2% of the US population.
• According to American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Women are five to eight times more likely than men to have thyroid problems.
• As per data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021), Graves’ disease affects nearly 1 in 100 Americans.
• According to Shang et al. (2024), an estimated 2.7–3.0% of the adult Chinese population—over 31 million individuals—are affected by one or more autoimmune diseases, a prevalence comparable to that seen in Western populations. The predominant contributors to this burden are autoimmune thyroid diseases and rheumatoid arthritis.
• The leading Graves’ Disease Companies such as Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
• Promising Graves’ Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

Recent Developments in Graves’ Disease Pipeline

The past year has witnessed several groundbreaking advancements in the Graves’ Disease and TED pipeline:

• May 2025 – Amgen announced that the UK MHRA approved TEPEZZA® (teprotumumab) for moderate-to-severe TED, making it the first authorized treatment in the UK for adult TED patients.
• May 2025 – Viridian Therapeutics received FDA Breakthrough Therapy Designation for veligrotug (veli), an anti-IGF-1R candidate for TED.
• January 2025 – Sling Therapeutics reported topline efficacy and safety results from its Phase 2b/3 LIDS trial of linsitinib, an oral IGF-1R inhibitor for TED.
• December 2024 – Viridian Therapeutics shared positive Phase 3 results from its THRIVE-2 trial of veligrotug in chronic TED patients.

These developments highlight the growing focus on thyroid-associated ophthalmopathy and underline the expanding pipeline beyond traditional Graves’ Disease therapies.

Gain a competitive edge in the Graves’ Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Graves’ Disease Treatment Drugs

Graves’ Disease Competitive Landscape

Globally, several pharmaceutical and biotech companies are working relentlessly to address the gaps in treatment. According to DelveInsight’s analysis, key companies in the Graves’ Disease pipeline include:

• TSHR Septerna
• Cyclopeptides advanceCOR
• EVOQ Therapeutics
• Worg Pharmaceuticals
• AV7 Limited
• Novartis Pharmaceuticals
• Immunovant Sciences GmbH
• And others

These companies are developing therapies that target TSH receptor modulation, IGF-1R inhibition, monoclonal antibodies, and novel small molecules.

Emerging Therapies in the Graves’ Disease Pipeline

The pipeline consists of therapies in different stages of development ranging from pre-clinical to late clinical phases. Some of the promising candidates include:

• Research Program (TSHR Septerna) – early-stage research focused on TSH receptor modulation.
• Cyclopeptides (advanceCOR) – peptide-based therapies with unique mechanisms.
• EVOQ Therapeutics Research Program – nanotechnology-driven approaches.
• WP-1302 (Worg Pharmaceuticals) – advancing in early clinical trials.
• K1-70 (AV7 Limited) – a monoclonal antibody targeting TSH receptor.
• CFZ533 (Novartis Pharmaceuticals) – a promising immunomodulatory therapy.
• Batoclimab (Immunovant Sciences GmbH) – a next-generation FcRn inhibitor with potential in autoimmune thyroid disorders.

These therapies are expected to reshape the Graves’ Disease treatment landscape in the coming years, particularly for patients who do not respond to standard care.

Download DelveInsight’s Graves’ Disease Market report today and stay ahead in this rapidly evolving field. @ Graves’ Disease Clinical Trials and FDA Approvals

Graves’ Disease Overview

Graves’ Disease is the most common cause of hyperthyroidism, affecting millions worldwide. It is an autoimmune disorder in which the immune system attacks the thyroid gland, leading to the overproduction of thyroid hormones. Symptoms include unexplained weight loss, rapid heartbeat, anxiety, tremors, goiter (enlarged thyroid), and bulging eyes (Graves’ ophthalmopathy or thyroid eye disease, TED).

Diagnosis is typically confirmed through blood tests measuring thyroid hormone levels, thyroid-stimulating immunoglobulins (TSIs), and imaging scans such as radioactive iodine uptake.

Traditional treatment options include antithyroid medications (methimazole, propylthiouracil), radioactive iodine therapy, and thyroidectomy (surgery). However, limitations such as relapse, side effects, and long-term complications have created unmet needs, fueling the search for novel biologics, monoclonal antibodies, and targeted therapies.

Graves’ Disease Pipeline by Route of Administration (RoA)

Emerging products are being developed in multiple formulations for improved efficacy, safety, and patient convenience:

• Oral
• Parenteral
• Intravenous (IV)
• Subcutaneous (SC)
• Topical

Graves’ Disease Molecule Types

Therapies under development also span a diverse range of molecule classes:

• Monoclonal Antibodies
• Peptides
• Polymers
• Small Molecules
• Gene Therapies

This diversity reflects the industry’s multifaceted approach to targeting different pathways involved in Graves’ Disease.

Discover key developments and opportunities in the Graves’ Disease Market. Click here to learn more from DelveInsight’s latest report @ Graves’ Disease Market Dynamics

Graves’ Disease Market Dynamics – Drivers and Barriers

Key Graves’ Disease Market Drivers

• Rising prevalence of Graves’ Disease worldwide
• Growing awareness of early diagnosis and treatment
• Increased R&D investments by pharma and biotech companies
• Breakthrough drug designations and accelerated approvals

Key Graves’ Disease Market Barriers

• High cost of biologic and antibody therapies
• Complications associated with traditional therapies
• Limited availability of targeted treatments in developing regions

Scope of the Graves’ Disease Market Report

• Coverage- 7MM
• Graves’ Disease Companies- Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals (SWX: NOVN), AV7 Limited, Medtronic (NYSE: MDT), Pfizer (NYSE: PFE), Sanguine Biosciences, Tourmaline Bio Inc. (NASDAQ: TRML), Horizon Pharma USA Inc., Viridian Therapeutics Inc. (NASDAQ: VRDN), Innovent Biologics Co. Ltd (HKEX: 1801), Hoffmann-La Roche (SWX: RO), and others.
• Graves’ Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
• Graves’ Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Graves’ Disease Unmet Needs, KOL’s views, Analyst’s views, Graves’ Disease Market Access and Reimbursement

Download the report to understand which factors are driving Graves’ Disease Market Dynamics @ Graves’ Disease Market Trends

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services